MetabolicUnregulated/Therapeutic
Retatrutide
Synonyms: LY3437943, Triple G
Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-diAsn-Ala-Phe-Val-Gln-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
History & Discovery Timeline
Retatrutide was developed by Eli Lilly and Company, entering Phase III trials in 2023 to offer superior efficacy over existing dual co-agonists.
What it is: Retatrutide is a synthetic 39-amino-acid peptide with triple agonist activity at the GIP, GLP-1, and s. It is categorized under the Metabolic category.
Proposed Mechanisms & Research Findings: By targeting GIP, GLP-1, and s, it increases insulin secretion, reduces food intake, and accelerates energy expenditure, showing unprecedented weight loss efficacy in clinical trials.
Regulatory & Safety Status: It is not FDA approved and is currently in Phase III clinical development. Online gray-market sourcing presents significant clinical and cardiovascular safety hazards.
Athletic & Anti-Doping Status: It is monitored by WADA and is not strictly prohibited, but is under evaluation due to its potent effects on metabolism and body weight.
Understanding Retatrutide Key Facts
Primary Target System:NEUROENDOCRINE
Residue Count / Length:41 Amino Acids
Primary Action & Category:Triple GLP-1/GIP/Glucagon Receptor Agonist (Metabolic)
Primary Receptors:GIP Receptor, GLP-1 Receptor, Glucagon Receptor
Figure 1: Detailed molecular mechanism pathways of Retatrutide (click to enlarge).